Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo de Buntanetap em Participantes com DP

28 de outubro de 2026 atualizado por: Annovis Bio Inc.

Um Ensaio Clínico Aberto que Investiga a Segurança a Longo Prazo do Buntanetap no Tratamento de Participantes com Doença de Parkinson

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Tipo de estudo

Intervencional

Inscrição (Estimado)

500

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Recrutamento
        • University of Alabama at Birmingham
        • Contato:
        • Investigador principal:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Estados Unidos, 85351
        • Recrutamento
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Investigador principal:
          • Sara Dhanani, M.D.
        • Contato:
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Recrutamento
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Investigador principal:
          • Daniel Truong, M.D.
        • Contato:
          • Evan Moreno-Davis
          • Número de telefone: 714-378-5074
          • E-mail: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Estados Unidos, 80113
        • Recrutamento
        • Cenexel Rocky Mountain Clinical Research
        • Contato:
        • Investigador principal:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Estados Unidos, 06824
        • Recrutamento
        • New England Institute for Clinical Research (Ki Health Partners)
        • Contato:
        • Investigador principal:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Estados Unidos, 33180
        • Recrutamento
        • First Choice Neurology - Aventura Neurologic Associates
        • Investigador principal:
          • Jonathan Cross, M.D.
        • Contato:
      • Daytona Beach, Florida, Estados Unidos, 32117
        • Recrutamento
        • Arrow Clinical Trials
        • Contato:
        • Investigador principal:
          • David Billmeier, M.D.
      • DeLand, Florida, Estados Unidos, 32720
        • Recrutamento
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Investigador principal:
          • Bruce Rankin, D.O.
        • Contato:
      • Miami, Florida, Estados Unidos, 33172
      • Miami, Florida, Estados Unidos, 33015
        • Ainda não está recrutando
        • Ezy Medical Research Co.
        • Contato:
      • Ocala, Florida, Estados Unidos, 34470
        • Recrutamento
        • Renstar Medical Research
        • Investigador principal:
          • Annette Nieves, M.D.
        • Contato:
      • Tampa, Florida, Estados Unidos, 33613
        • Recrutamento
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Contato:
        • Investigador principal:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Estados Unidos, 32789
        • Recrutamento
        • Conquest Research
        • Contato:
        • Investigador principal:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur, Georgia, Estados Unidos, 30030
        • Recrutamento
        • iResearch Atlanta
        • Contato:
        • Investigador principal:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Recrutamento
        • Josephson Wallack Munshower Neurology, P.C.
        • Investigador principal:
          • Kristi George, M.D.
        • Contato:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Recrutamento
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Contato:
        • Investigador principal:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Recrutamento
        • Quest Research Institute
        • Investigador principal:
          • Aaron Ellenbogen, D.O.
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10019
        • Recrutamento
        • Mount Sinai Hospital
        • Investigador principal:
          • Joohi Jimenez-Shahed, M.D.
        • Contato:
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Recrutamento
        • Duke Department of Neurosurgery
        • Investigador principal:
          • Kyle Mitchell, M.D.
        • Contato:
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The Ohio State University Wexner Medical Center
        • Investigador principal:
          • Zachary Jordan, M.D.
        • Contato:
    • Oklahoma
      • Tulsa, Oklahoma, Estados Unidos, 74136
        • Recrutamento
        • The Movement Disorder Clinic of Oklahoma
        • Contato:
        • Investigador principal:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Estados Unidos, 19090
        • Recrutamento
        • Abington Neurology
        • Investigador principal:
          • David Weisman, M.D.
        • Contato:
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29401
        • Recrutamento
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Contato:
        • Investigador principal:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Estados Unidos, 38018
        • Recrutamento
        • Neurology Clinic, P.C.
        • Contato:
        • Investigador principal:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Estados Unidos, 38157
        • Recrutamento
        • Veracity Neuroscience LLC
        • Contato:
        • Investigador principal:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Estados Unidos, 78681
        • Recrutamento
        • Central Texas Neurology
        • Contato:
        • Investigador principal:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22903
        • Recrutamento
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Investigador principal:
          • Binit Shah, M.D.
        • Contato:
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Recrutamento
        • Inland Northwest Research
        • Investigador principal:
          • Jason Aldred, M.D.
        • Contato:
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Recrutamento
        • Medical College of Wisconsin
        • Contato:
        • Investigador principal:
          • Karen Blindauer, M.D.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

40 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Experimental: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety of buntanetap
Prazo: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Prazo: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Prazo: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Prazo: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de janeiro de 2026

Conclusão Primária (Estimado)

1 de setembro de 2029

Conclusão do estudo (Estimado)

1 de novembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

26 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de dezembro de 2025

Primeira postagem (Real)

16 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ANVS-25002

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .